Corcept Therapeutics Incorporated (CORT)
Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?
Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.
Corcept Grows to Mid-Cap on Institutional Support
Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.
Corcept: Not Cheap, But Backed By Real Structural Growth
Corcept Therapeutics is evolving into a multi-engine growth platform, driven by expanding Cushing's and a rapid oncology ramp with Lifyorli. CORT delivered strong 2Q26 results: $256.1M revenue (+32% YoY), $47.6M Lifyorli launch, and maintained profitability despite elevated launch expenses. CATALYST and MOMENTUM studies reveal Cushing's is more prevalent than previously thought, structurally expanding the addressable market and supporting multi-billion-dollar revenue potential.
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Trump is up 230% on this stock trade since March
President Donald Trump disclosed a position in Corcept Therapeutics (NASDAQ: CORT) on March 4, when the pharmaceutical company was trading at $35.69.
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Raised Guidance Lifts Corcept to 52-Week High
CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol (over 1,000 proprietary modulators) as well as Cushing's syndrome.
CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised
Corcept tops Q2 earnings estimates as Korlym growth and a strong Lifyorli launch lift revenues, prompting a higher 2026 top-line outlook.
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.29 per share a year ago.
Corcept Therapeutics Q2 Earnings Call Highlights
Corcept Therapeutics NASDAQ: CORT reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing's syndrome franchise increased and its newly launched ovarian cancer therapy LIFYORLI contributed $47.6 million in its first quarter of availability.
Are Medical Stocks Lagging Corcept Therapeutics (CORT) This Year?
Here is how Corcept Therapeutics (CORT) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook
The transaction realized $1.9 million in gross proceeds on July 7, 2026, at a weighted average price of $93.13 per share. The disposition was a cashless exercise of 20,000 options at a strike price of $21.65, followed by an immediate open-market sale.
